| Literature DB >> 33216966 |
Jithma P Abeykoon1, David L Murray2, Isaiah Murray2, Dragan Jevremovic2, Gregory E Otteson2, Angela Dispenzieri1, Bonnie K Arendt2, Surendra Dasari3, Morie Gertz1, Wilson I Gonsalves1, Taxiarchis V Kourelis1, Eli Muchtar1, David Dingli1, Rahma Warsame1, Ronald S Go1, Martha Q Lacy1, Nelson Leung1, Francis Buadi1, Yi Lin1, Robert A Kyle1, Vincent Rajkumar1, Shaji Kumar1, Prashant Kapoor1.
Abstract
Measurable residual disease (MRD) assessment by marrow-based next-generation flow cytometry (NGF) following autologous stem cell transplantation (ASCT) may lead to false-negative results due to patchy marrow involvement and extramedullary disease in patients with multiple myeloma. We assessed the value of simultaneous MRD evaluation with NGF and serum matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MASS-FIX). Of all 61 complete responders who were NGF-negative for MRD, around day-100 post ASCT, 59% were MASS-FIX-positive. At median follow-up of 26 months, 69% of MASS-FIX(+)/NGF(-) patients were alive and progression-free versus 96% of MASS-FIX(-)/NGF(-) patients, P = 0·02. MASS-FIX, a simple peripheral blood-based assay complements marrow-based NGF to accurately prognosticate patients with myeloma.Entities:
Keywords: mass spectroscopy; measurable residual disease; prognosis
Year: 2020 PMID： 33216966 DOI： 10.1111/bjh.17195
Source DB: PubMed Journal: Br J Haematol ISSN： 0007-1048 Impact factor: 6.998